Attached files

file filename
EX-31 - Q BioMed Inc.exhibit31.htm
EX-32 - Q BioMed Inc.exhibit32.htm
 
 


 


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 10-Q/A

 
[X]
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
   
For the quarterly period ended: August 31, 2015
 
Or
 
[  ]
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
   
For the transition period from ____________ to _____________
 
Commission File Number: 333-193328
 
 Q BIOMED INC.
(Exact name of registrant as specified in its charter)
 
Nevada
46-4013793
(State or other jurisdiction of incorporation or organization)
(I.R.S. Employer Identification No.)
   
c/o Sanders Ortoli Vaughn-Flam Rosenstadt LLP
501 Madison Ave. 14th Floor
New York, NY10022
(Address of principal executive offices)
   
(212) 588-0022
(Registrant's telephone number, including area code)
 
 
(Former name, former address and former fiscal year, if changed since last report)
 
Indicate by check mark whether the issuer (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the past 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
Yes x    Noo

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).  Yesx   Noo

Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company.  See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.:

Large accelerated filer o
Accelerated filer o
Non-accelerated filer   o   (Do not check if a smaller reporting company)
Smaller reporting company x

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act)
Yesx    Noo

Indicate the number of shares outstanding of each of the issuer's classes of common stock, as of the latest practicable date:

Common Stock, $0.001 par value
8,375,000 shares
(Class)
(Outstanding as at October 15, 2015)

 
 

 


Explanatory Note
 
We are filing this Amendment No. 1 (the “Amendment”) on Form 10-Q/A to amend our Quarterly Report on Form 10-Q for the three months ended August 31, 2015 (the “Original Filing”) that was filed with the Securities and Exchange Commission on October 20, 2015, solely for the purpose of furnishing Exhibits 31 and 32 that were excluded from the Original Filing.

Except as described above, this Amendment No. 1 does not amend any other information set forth in the Original Filing, and the Company has not updated disclosures included therein to reflect any events that occurred subsequent to October 20, 2015.

Item 6. Exhibits and Reports on Form 8-K

Exhibit Number
Name and/or Identification of Exhibit
   
3
Articles of Incorporation & By-Laws
   
 
(a) Articles of Incorporation (1)
 
(b) By-Laws (1)
   
31
Rule 13a-14(a)/15d-14(a) Certifications
   
32
Certification under Section 906 of the Sarbanes-Oxley Act (18 U.S.C. Section 1350)
   
101
Interactive Data File
   
 
(INS) XBRL Instance Document(2)
 
(SCH) XBRL Taxonomy Extension Schema Document(2)
 
(CAL) XBRL Taxonomy Extension Calculation Linkbase Document(2)
 
(DEF) XBRL Taxonomy Extension Definition Linkbase Document(2)
 
(LAB) XBRL Taxonomy Extension Label Linkbase Document(2)
 
(PRE) XBRL Taxonomy Extension Presentation Linkbase Document(2)
   
(1)  
Incorporated by reference to the Registration Statement on Form S-1/A, previously filed with the SEC on January 13, 2014.
(2)  
Incorporated by reference to the Original Filing.



8-K Filed Date
Item Number
   
August 8, 2015
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
 
Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
 
Item 9.01 Financial Statements and Exhibits


 
 

 

SIGNATURES

Pursuant to the requirements of the Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Q BIOMED INC.
(Registrant)
 
Signature
Title
Date
     
/s/  Denis Corin
Chief Executive Officer
and President
October 23, 2015
Denis Corin
   
     
/s/ Denis Corin
Principal Accounting Officer
October 23, 2015
Denis Corin
Principal Financial Officer